Search

Objective: To investigate the correlation between fractional exhaled nitric oxide (FeNO), asthma control in children and different subtypes of asthma. Methods: 60 children with bronchial asthma and bronchiolitis who were diagnosed in our hospital from January 2017 to January 2018 were selected. They were divided to asthma group and bronchiolitis group. In addition, 40 healthy children who underwent physical examination for non-respiratory diseases in the same period in our hospital were selected as the control group. The FeNO of asthma group and bronchiolitis group were measured before treatment, 1 h after treatment and 4 weeks after treatment. FeNO was measured in the control group at the time of physical examination. The changes of FeNO concentration in control group at the time of physical examination, asthma group and bronchiolitis group at different stages of treatment were compared. children in the asthma group were divide into the asthma controlled group, asthma part controlled group and asthma uncontrolled group according to their asthma control status, and divided into cough variant group and non-cough variant group according to their asthma subtypes. The correlation between FeNO, asthma control and asthma subtypes in children with asthma were analyzed. Results: The concentration of FeNO in asthma group before treatment was higher than that in bronchiolitis group before treatment and control group at the time of physical examination( P<0.05). Compared with before and 1 h after treatment, the concentration of FeNO in asthmatic group and bronchiolitis group decreased significantly at 4 weeks after treatment (P<0.05). The concentration of FeNO in asthma group was higher than that in bronchiolitis group 1 h after treatment and 4 weeks after treatment (P<0.05). The concentration of FeNO in asthma controlled group were significantly lower than asthma part controlled group and asthma uncontrolled group. The concentration of FeNO in asthma part controlled group was lower than that in asthma uncontrolled group. The concentration of FeNO in cough variance group was higher than that in non-cough variance group (P<0.05). The concentration of FeNO was negatively correlated with disease control, the lower the concentration of FeNO, the better the disease controlled (r=-0.512, P=0.034).Conclusions: The concentration of FeNO in children with asthmatic was significantly higher than that in children with bronchiolitis and healthy children. It has correlation with asthma control, and can be used as an auxiliary diagnostic index for children with asthma. [ABSTRACT FROM AUTHOR]

Objective: To explore the clinical effect of budesonide combined with montelukast sodium in the treatment of children with asthma and it’s effect on the immune function, serum cysteine leukotriene(Cys LTs) and the expression of 5-lipoxygenase activator protein(FLAP). Methods: 118 cases of bronchial asthma were selected in our hospital from March 2015 to January 2017, and divided them into control group and observation group according to the principle of randomization, with 59 cases in each group. The control group was treated with Budesonide Aerosol, and the observation group was treated with montelukast sodium on the basis of the control group. The clinical effect and the changes of lung function, immune index, Cys LTs, FLAP level and clinical effect between the two groups before and after treatment were compared and analyzed. Results: After treatment, the total effective rate of the observation group(93.22%) was significantly higher than that of the control group(77.97%)(P<0.05); the index of FEV1, FVC and FEV1/FVC in two groups increased significantly compared with those before treatment(P <0.05), and the index of FEV1, FVC and FEV1/FVC in the observation group were significantly higher than those in the control group(P <0.05); the CD4+and CD4+/CD8+of two groups were significantly increased before treatment, and CD8+was significantly lower than before treatment(P<0.05), the CD4+and CD4+/CD8+in the observation group were significantly higher than those in the control group, and the CD8+was significantly lower than the control group(P<0.05); the two groups of Cys LTs and FLAP were significantly lower than those before treatment(P<0.05), and the Cys LTs and FLAP in the observation group were significantly lower than those in the control group(P <0.05). Conclusions: The combination of budesonide and montelukast can effectively improve the clinical efficacy and improve the pulmonary function of children with asthma.The mechanism may be related to the enhancement of immune function and the reduction of the expression of serum Cys LTs and FLAP. [ABSTRACT FROM AUTHOR]